These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37381597)

  • 21. Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer.
    Kim KN; Shah P; Clark A; Freedman GM; Dastgheyb S; Barsky AR; Dreyfuss AD; Taunk NK
    Breast; 2021 Dec; 60():163-167. PubMed ID: 34653725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
    Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
    Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
    Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
    Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
    Ratosa I; Orazem M; Scoccimarro E; Steinacher M; Dominici L; Aquilano M; Cerbai C; Desideri I; Ribnikar D; Marinko T; Livi L; Meattini I
    Clin Breast Cancer; 2020 Dec; 20(6):495-502. PubMed ID: 32622736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
    Behrouzi R; Armstrong AC; Howell SJ
    Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta.
    Amaro CP; Batra A; Lupichuk S
    Curr Oncol; 2021 Jun; 28(3):2270-2280. PubMed ID: 34207443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
    Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
    Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Alvarez A; Bernal AM; Anampa J
    Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
    Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
    JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data.
    Kubeczko M; Gabryś D; Polakiewicz-Gilowska A; Bobek-Billewicz B; Jarząb M
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biological, preclinical and clinical aspects of the association between radiation therapy and CDK4/6 inhibitors].
    Beddok A; Porte B; Cottu P; Fourquet A; Kirova Y
    Cancer Radiother; 2023 May; 27(3):240-248. PubMed ID: 37080859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report:
    Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
    Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
    Pernin V; Belin L; Cottu P; Bontemps P; Lemanski C; De La Lande B; Baumann P; Missohou F; Levy C; Peignaux K; Reynaud-Bougnoux A; Denis F; Gobillion A; Bollet M; Vago NA; Dendale R; Campana F; Fourquet A; Kirova YM
    Br J Radiol; 2015 Apr; 88(1048):20140800. PubMed ID: 25645108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy.
    Kim KN; Salerno M; Shah PD; Matro J; LaRiviere MJ
    J Oncol Pharm Pract; 2023 Apr; 29(3):764-767. PubMed ID: 35929120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
    Sakach E; Keskinkilic M; Wood S; Canning M; Kalinsky K
    Curr Treat Options Oncol; 2023 Sep; 24(9):1103-1119. PubMed ID: 37314645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
    Kruse M; Smyth EN; Bowman L; Gautam S; Guimaraes CM; Nisbett AR; Fisher MD; Cui ZL; Sheffield KM; Kalinsky K
    Breast Cancer Res Treat; 2023 Aug; 201(1):105-115. PubMed ID: 37310540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer.
    Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL
    Breast Cancer Res Treat; 2023 Jul; 200(1):85-92. PubMed ID: 37157005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.